NASDAQ: GYREGyre Therapeutics Inc Stock
$8.13+0.33 (+4.23%)
Updated Jul 3, 2025
GYRE Price
$8.13
Fair Value Price
-$3.33
Market Cap
$762.25M
52 Week Low
$6.11
52 Week High
$19.00
P/E
101.63x
P/B
11.19x
P/S
6.63x
PEG
0.57x
Dividend Yield
N/A
Revenue
$100.64M
Earnings
$7.25M
Gross Margin
96.2%
Operating Margin
10.86%
Profit Margin
7.2%
Debt to Equity
0.37
Operating Cash Flow
-$7M
Beta
1.21
Next Earnings
Aug 19, 2025
Ex-Dividend
N/A
Next Dividend
N/A
GYRE Overview
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GYRE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GYRE
Ranked#83 of 468
Ranked#83 of 468
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.59 | A | |
| $3.58 | A | |
| $46.15 | A |
Be the first to know about important GYRE news, forecast changes, insider trades & much more!
GYRE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GYRE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GYRE ($8.13) is overvalued by 344.22% relative to our estimate of its Fair Value price of -$3.33 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GYRE ($8.13) is not significantly undervalued (344.22%) relative to our estimate of its Fair Value price of -$3.33 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GYRE ($8.13) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more GYRE due diligence checks available for Premium users.
Valuation
GYRE fair value
Fair Value of GYRE stock based on Discounted Cash Flow (DCF)
Price
$8.13
Fair Value
-$3.33
Undervalued by
344.22%
GYRE ($8.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GYRE ($8.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GYRE ($8.13) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GYRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
101.63x
Industry
-154.26x
Market
30.96x
GYRE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GYRE is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
GYRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.19x
Industry
4.54x
GYRE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GYRE price to earnings growth (PEG)
For valuing profitable companies with growth potential
GYRE is good value based... subscribe to Premium to read more.
PEG Value Valuation
GYRE's financial health
Profit margin
Revenue
$22.1M
Net Income
$2.7M
Profit Margin
12.2%
GYRE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GYRE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$129.8M
Liabilities
$25.5M
Debt to equity
0.37
GYRE's short-term assets ($68.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GYRE's short-term assets ($68.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GYRE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GYRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$129.0k
Investing
$2.0M
Financing
$1.3M
GYRE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GYRE vs Biotech Stocks
Gyre Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.